Adult Patients
Designed to be simple in a severe hypoglycemia rescue
Product features1:
- Dry nasal powder form of glucagon
- No inhalation required—absorbed passively in the nose
- Single, fixed, 3 mg dose
- Ready to use with no reconstitution or priming
- Does not need to be refrigerated, store at temperatures up to 86°F (30°C) in the shrink-wrapped tube provided
BAQSIMI can be used for 2 years from the date of manufacture. Instruct patients to check the expiration date on the BAQSIMI tube and carton before use.1,3
INDICATION
BAQSIMI® is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
BAQSIMI is contraindicated in patients with pheochromocytoma because of risk of substantial increase in blood pressure, insulinoma because of risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.
In a severe hypoglycemia emergency, BAQSIMI offers:
1. Comparable efficacy to glucagon for injection in adults 1, *
Treatment success† for BAQSIMI and glucagon for injection
View Description
Two bar graphs show measures of treatment success for BAQSIMI (3 milligrams) and for glucagon for injection (1 milligram). In Study 1, 100 percent of patients treated with BAQSIMI and 100 percent of patients treated with glucagon for injection achieved treatment success as defined in the study. In Study 2, 98.8 percent of patients treated with BAQSIMI and 100 percent of patients treated with glucagon for injection achieved treatment success as defined in the study.
*In study 1, the mean nadir blood glucose was 54.5 mg/dL for BAQSIMI and 55.8 mg/dL for glucagon for injection. In study 2, the mean nadir blood glucose was 44.2 mg/dL for BAQSIMI and 47.2 mg/dL for glucagon for injection.
†Treatment success was defined as an increase in plasma glucose to ≥70 mg/dL or an increase of ≥20 mg/dL from glucose nadir within 30 minutes of receiving the study glucagon.
Study Design
- Two randomized, multicenter, open-label, 2-period crossover trials compared a 3 mg dose of nasally administered BAQSIMI to a 1 mg dose of glucagon for injection (IM) for treatment of insulin-induced hypoglycemia.
- Study 1 included 70 adult patients with type 1 diabetes; 66 patients were included in the efficacy analysis. Study 2 included 83 adult patients with type 1 or type 2 diabetes; 80 patients were included in the efficacy analysis.
- Primary efficacy measure was the proportion of patients achieving treatment success.
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
2. Portable dry nasal spray glucagon 1, 2
Be prepared with BAQSIMI. The first and only dry nasal spray to treat low blood sugar emergencies
BAQSIMI offers temperature-stable portability.
Patients can carry it with them throughout the day, in hot or cold conditions, and store at up to 86°F (30°C).
BAQSIMI can be taken with you, even in freezing temperatures.
In a study, BAQSIMI was exposed to freezing temperatures as low as -4°F (-20°C) with no adverse effects to the physical, chemical, or performance characteristics of the product.
BAQSIMI can be stored for two years from date of manufacture in the shrink-wrapped tube provided, at temperatures up to 86°F (30°C). Always check the expiration date on the BAQSIMI tube and carton before use.1,3
3. Simplicity of nasal administration 2, 4
Before BAQSIMI is needed:
- Read the Instructions for Use for BAQSIMI before using it.
- You should make sure you show your caregivers, family and friends where you keep BAQSIMI and explain how to use it by sharing these instructions. They need to know how to use BAQSIMI before an emergency happens.
Important information to know:
- Do not remove the Shrink Wrap or open the Tube until you are ready to use it.
- If the Tube has been opened, BAQSIMI could be exposed to moisture. This could cause BAQSIMI not to work as expected.
- BAQSIMI will work even if you have a cold or are taking cold medicine.
Preparing the dose:
Remove the Shrink Wrap by pulling on the red stripe.
Open the Lid and remove the Device from the Tube.
Caution: Do not press the Plunger until ready to give the dose.
Giving the dose
Hold Device between fingers and thumb.
Do not push Plunger yet.
Insert Tip gently in one nostril until finger(s) touch the outside of the nose.
Push Plunger firmly all the way in. Dose is complete when the Green Line disappears.
After giving BAQSIMI:
- Call for emergency medical help right away
- If the person is unconscious, turn the person on their side
- Throw away the used Device and Tube
- Encourage the person to eat as soon as possible. When they are able to safely swallow, give the person a fast-acting source of sugar, such as juice. Then encourage the person to eat a snack, such as crackers with cheese or peanut butter
- If the person does not respond after 15 minutes, another dose may be given, if available
Discover the simplicity of nasal administration with BAQSIMI
References:
- Baqsimi. Prescribing Information. Amphastar Pharmaceuticals, Inc.
- Pack BW, Melnick J, Breen C, Allen R. Portability of nasal glucagon for the rescue of severe hypoglycemia: stability and performance evaluation across a broad range of temperatures. Diabetes. 2021; 70(suppl 1).
- Data on File, Amphastar Pharmaceuticals, Inc..
- Baqsimi. Instructions For Use. Amphastar Pharmaceuticals, Inc..